According to Zacks, “Motif Bio plc is a biopharmaceutical company. It engaged in the research and development of antibiotics for serious and life-threatening infections caused by multi-drug resistant bacteria. The company’s product pipeline includes Iclaprim, REVIVE-1 and REVIVE-2 which are in clinical stage. Motif Bio plc is headquartered in London, UK. “
Separately, Northland Securities set a $5.00 target price on shares of MOTIF BIO PLC/S and gave the stock a buy rating in a research note on Monday, July 15th.
An institutional investor recently bought a new position in MOTIF BIO PLC/S stock. Virtu Financial LLC bought a new position in shares of MOTIF BIO PLC/S (NASDAQ:MTFB) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 19,865 shares of the company’s stock, valued at approximately $36,000. Virtu Financial LLC owned about 0.13% of MOTIF BIO PLC/S as of its most recent SEC filing. 7.58% of the stock is currently owned by institutional investors.
MOTIF BIO PLC/S Company Profile
Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MOTIF BIO PLC/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MOTIF BIO PLC/S and related companies with MarketBeat.com's FREE daily email newsletter.